LUMEN BIOSCIENCE
Lumen Bio is a clinical-stage biotechnology company developing topically and mucosally delivered biologic drugs to treat and prevent highly prevalent diseases.
LUMEN BIOSCIENCE
Industry:
Biopharma Biotechnology Life Science
Founded:
2017-04-01
Address:
Seattle, Washington, United States
Country:
United States
Website Url:
http://www.lumen.bio
Total Employee:
51+
Status:
Active
Contact:
206-899-1904
Total Funding:
47.5 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail IPv6 Google Google DNS Google Domains Google Cloud DNS NetSuite Mail
Similar Organizations
ArcherDX
ArcherDX is a biotechnology firm specializing in cancer research.
Bicara Therapeutics
Bicara Therapeutics develops dual-action cancer therapies, combining targeted treatments with tumor modulators for enhanced impact.
Castle Creek Biosciences
Castle Creek Biosciences is focused on developing commercializing novel, personalized gene therapies for rare skin disorders.
Cerevance
Cerevance is a developer of novel therapeutics intended to advance new medicines for serious neurological diseases.
Demetrix
Demetrix is a biotechnology company dedicated to researching and producing bioactive ingredients.
Enliven Therapeutics
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Sunshine Biopharma
Sunshine Biopharma focuses on the research, development, and commercialization of drugs for the treatment of various forms of cancer.
Current Advisors List
Current Employees Featured
Founder
Investors List
CARB-X
CARB-X investment in Grant - Lumen Bioscience
U.S. Army Medical Research & Development Command
U.S. Army Medical Research & Development Command investment in Grant - Lumen Bioscience
Avista Development
Avista Development investment in Series B - Lumen Bioscience
WestRiver Group
WestRiver Group investment in Series B - Lumen Bioscience
Columbia Pacific Advisors
Columbia Pacific Advisors investment in Series B - Lumen Bioscience
Bioeconomy Capital
Bioeconomy Capital investment in Series B - Lumen Bioscience
US Department of Energy
US Department of Energy investment in Grant - Lumen Bioscience
Avista Development
Avista Development investment in Series A - Lumen Bioscience
Bioeconomy Capital
Bioeconomy Capital investment in Series A - Lumen Bioscience
Key Employee Changes
| Date | New article |
|---|---|
| 2020-09-10 | Lumen hires Spigarelli as CMO to lead infectious disease pipeline work |
Official Site Inspections
http://www.lumen.bio Semrush global rank: 8.73 M Semrush visits lastest month: 261
- Host name: 23.185.0.1
- IP address: 23.185.0.1
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Lumen Bioscience"
Homepage | Lumen Bioscience
The Innovator's Dilemma with Lumen Bioscience's Brian Finrow, J.D. March 4th, 2024 Lumen Bioscience cracks the code on spirulina as a biologics factory for c. diff, …See details»
Lumen Bioscience Details 2022 Company and Facilities Growth, …
Jan 5, 2023 Lumen also made strong progress in the CARB-X-funded program to develop a broad antibody cocktail offering protection against most clinically important strains of ETEC …See details»
Lumen Bioscience - Crunchbase Company Profile
Lumen Bioscience develops and manufactures biologic drugs and vaccine candidates using a technology platform that allows for rapid and cost-effective production. C. difficile Colitis Treatment A product candidate targeting C. …See details»
Lumen Bioscience Details 2022 Company and Facilities …
Jan 5, 2023 LMN-301 for Covid-19 – In 2022, Lumen Bio's Covid-19 funding consortium expanded to include BARDA and the Bill & Melinda Gates Foundation. Strong preclinical data with an intranasal formulation ...See details»
Lumen Bioscience Details 2022 Company and Facilities Growth
Jan 5, 2023 Lumen also made strong progress in the CARB-X-funded program to develop a broad antibody cocktail offering protection against most clinically important strains of ETEC …See details»
Lumen Bio: ‘We face 2023 with tremendous optimism’
Jan 16, 2023 Lumen Bioscience has been highlighting recent progress made on its clinical and regulatory journey while also announcing several funding milestones supporting the development of its therapeutics to prevent serious …See details»
Lumen Bioscience Awarded Federal Grant to Rapidly …
Sep 24, 2020 Lumen Bioscience discovers, develops, and manufactures biologic drugs and vaccine candidates for several prevalent, worldwide diseases—many of which currently lack any effective treatments.See details»
Executive Bios - Lumen Newsroom
Not all products and services are available in all regions and countries; please contact a representative near you for details.See details»
Lumen Bioscience: Spirulina-based platform enables …
Apr 7, 2022 Lumen is currently applying the technology to a growing list of highly prevalent diseases. Its oldest program is Gates Foundation led – it is a single antibody directed at preventing infection by the most common strain of C. …See details»
CARB-X is funding Seattle-based Lumen Bioscience to develop a …
The World Health Organization (WHO) estimates that 700,000 people die each year from drug-resistant infections, including 35,000 in the US and 33,000 in Europe. ... [email protected]. …See details»
Science | Lumen Bioscience
Lumen was the first to achieve this breakthrough, and this in turn makes orally delivered biologics commercially viable for the first time. Daily, high-dose biologic drug We design and …See details»
Lumen Bioscience Announces Publication in Nature Biotechnology ...
Mar 21, 2022 About Lumen Lumen Bioscience discovers, develops, and manufactures biologic drug candidates for highly prevalent diseases—many of which currently lack any effective …See details»
Lumen Bioscience and Novo Nordisk Enter into Research …
Jun 16, 2021 Lumen's clinical pipeline includes investigational biologic drugs for C. difficile infection, inflammatory bowel disease, Covid-19, norovirus, and traveler's diarrhea. For more …See details»
News | Lumen Bioscience
Oct 11, 2023 Lumen Bioscience cracks the code on spirulina as a biologics factory for c. diff, metabolic disease and more. January 19th, 2024. Lumen Bioscience bags $5.5 million to …See details»
7: Module 5- The Tissue Level of Organization - Biology LibreTexts
Feb 28, 2021 7.1: Introduction to the Tissue Level of Organization; 7.2: Types of Tissues; 7.3: Epithelial Tissue; 7.4: Connective Tissue Supports and Protects; 7.5: Muscle Tissue and …See details»
Lumen Bioscience Awarded Federal Funding to Advance Covid-19 …
Oct 6, 2021 The Lumen Bio product under development, LMN-301, is a cocktail of antibody-like proteins that bind to the spike protein of SARS-CoV-2 and prevent it from infecting the ACE2 …See details»
4.4: Levels of Organization of Living Things - Biology LibreTexts
Feb 28, 2021 Biology for Majors II (Lumen) 4: Module 1- Introduction to Biology 4.4: Levels of Organization of Living Things ... At the highest level of organization (Figure 2), the biosphere is …See details»
Pipeline | Lumen Bioscience
Lumen’s platform offers a way to address these diseases in a way that is both targeted and affordable. Other Long-Term Targets. Once drug developers come to fully appreciate the …See details»
4.4: Levels of Organization of Living Things - Biology LibreTexts
Feb 28, 2021 Biology for Non Majors II (Lumen) 4: Module 1- Introduction to Biology 4.4: Levels of Organization of Living Things ... At the highest level of organization (Figure 2), the …See details»